Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Novo Nordisk —"


25 mentions found


Crypto stocks – Shares of Coinbase surged 12% as investors cheered the prospect of a more supportive regulatory environment for cryptocurrency businesses under a second Donald Trump presidency. Bank stocks — Shares of banking stocks soared in premarket trading after Donald Trump's victory spurred investor optimism that the sector could see less regulation . CVS Health — Shares rose 7.5% after CVS posted mixed third-quarter results , citing higher medical costs that weighed on net income. Clean energy stocks — Shares of renewable energy and solar companies slid on worries that Trump's second term could imperil the Inflation Reduction Act and measures to fight climate change. Dollar Tree , Five Below — Shares of Dollar Tree slipped 1.6%, while Five Below moved down 9%.
Persons: Donald Trump, Donald Trump's, Goldman Sachs, Wells Fargo, SunRun, FirstSolar, Wegovy, Trump, CoreCivic, Dan Ives, Tesla, — CNBC's Michelle Fox Theobald, Tanaya Macheel, Brian Evans Organizations: MicroStrategy, Bank, , Citigroup, Bank of America, Trump Media & Technology, Republican, CVS, Enphase Energy, Novo Nordisk —, GEO Group, Elon, Trump, Wedbush Securities, Tilray, Aurora Cannabis, National Retail Federation Locations: FactSet, Novo Nordisk — U.S, Danish, U.S, Florida, Canada, China
Crypto stocks — Cryptocurrency-related names soared after investors bet that a Trump presidency would lead to a more supportive regulatory environment. Cannabis stocks — Shares of cannabis companies dropped after voters rejected a Florida ballot measure to legalize the sale and use of marijuana in the state. Dollar Tree and Dollar General also respectively lost more than 6% and 5%. Steel stocks — U.S.-based steel stocks rallied on the back of Trump's victory. Shares of Nucor and Cleveland-Cliffs respectively rallied 16% and 20%, while United States Steel climbed 8%.
Persons: Donald Trump, Donald Trump's, Trump, Tesla, bitcoin, Goldman Sachs, Wells, Joe Biden's, Sunrun, Wegovy, CoreCivic, Trump's, — CNBC's Michelle Fox, Alex Harring, Hakyung Kim, Sarah Min, Samantha Subin Organizations: Republican, Trump Media & Technology, Bank, Citigroup, Bank of America, Wells Fargo, CVS Health, CVS, Trump, SolarEdge Technologies, Enphase Energy, Novo Nordisk —, Novo Nordisk, — Geo, White, Aurora Cannabis, , CNBC, Holdings, Steel, U.S, Cliffs, United States Steel Locations: Novo Nordisk — U.S, Danish, Florida, Tilray, U.S, Canada, China, Cleveland
Costco Wholesale — The membership-only retailer saw shares dip about 1% after the company missed expectations for fiscal fourth-quarter revenue. Super Micro Computer — Shares of the artificial intelligence beneficiary slipped 2%, adding to their 12% loss in the previous session. The Wall Street Journal reported that the U.S. Justice Department had opened a probe on the company. Dollar General — Shares fell 2% after Citi downgraded Dollar General to sell from neutral, saying Walmart 's increasing dominance in retail, especially on pricing, has the dollar store "on the wrong side." HP Inc. — The tech hardware stock fell about 2% after a downgrade to neutral from buy at Bank of America.
Persons: Myers Squibb, Costco, Hindenburg, Morgan Stanley, , KeyBanc, — CNBC's Hakyung Kim, Lisa Kailai Han, Yun Li, Sarah Min, Jesse Pound, Samantha Subin, Michelle Fox Organizations: Myers, U.S . Food, Drug Administration, Novo Nordisk —, JPMorgan, Costco Wholesale, Revenue, Street Journal, U.S . Justice Department, U.S . Securities, Exchange Commission, Wynn Resorts, Citi, Walmart, HP Inc, Bank of America, HP Locations: Bristol, U.S, Novo Nordisk — U.S, Danish
That came after short-seller Hindenburg Research revealed last month it had taken a short position in the company, citing "fresh evidence of accounting manipulation." Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley. Amgen — The biotech's shares rose 2% after Cantor Fitzgerald initiated research coverage with an overweight rating. — The aerospace and defense stock added 16% following a price target increase from KeyBanc Capital Markets, which retained an overweight investment rating.
Persons: Bristol Myers, Hindenburg, Morgan Stanley, Amgen, Cantor Fitzgerald, Olivia Brayer, Michael Leshock, — CNBC's Sean Conlon, Alex Harring, Yun Li, Hakyung Kim, Samantha Subin, Pia Singh Organizations: Bristol Myers Squibb, Food and Drug Administration, Bristol, Nordisk —, JPMorgan, Wall, Costco Wholesale, Revenue, Wall Street Journal, Justice Department, Hindenburg Research, Securities and Exchange Commission, Wynn Resorts, UAE, HP Inc, Bank of America, KeyBanc Locations: Nordisk — U.S, Danish, Las Vegas
The head of the committee, Sen. Bernie Sanders, I-Vt., has been vocal about his frustrations over how much Novo Nordisk charges Americans for both Ozempic (used to treat type 2 diabetes) and Wegovy (approved for weight loss). Mariam Zuhaib / AP“It is clear that Novo Nordisk is ripping off the American people,” Sanders told NBC News in June. In a statement Monday, Novo Nordisk defended its pricing structure. Novo Nordisk holds the patent on semaglutide, so other companies aren't able to make a generic version. That leaves Novo Nordisk — and ultimately Jørgensen — to answer questions about the price of its blockbuster drugs.
Persons: Lars Fruergaard Jørgensen, Jørgensen, Sen, Bernie Sanders, Sanders, Mariam Zuhaib, ” Sanders, , United States don’t, Organizations: Nordisk, Capitol, Health, Education, Labor, Pensions, NBC News, Novo Nordisk, Department of Health, Human Services, NBC, Novo Nordisk — Locations: Canada, Europe, United States, Germany, United Kingdom, U.S, Novo
Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.
Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, , didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah
CNBC's Jim Cramer on Wednesday gave his take on Hims & Hers Health , a digital platform that offers telehealth services, particularly for sexual health, mental health, weight loss and skin care. Cramer suggested it might be worth starting a position in the stock now that it's pulled back some from recent highs. "While it makes sense that the stock roared on this compounded GLP-1 news, I don't love that it's now trading on what's essentially a temporary business," he said. Those great first quarter numbers didn't have any benefit from knock-off GLP-1s, and I bet the business stays strong." Hims & Hers Health did not respond immediately to request for comment.
Persons: CNBC's Jim Cramer, Cramer, it's, I'd, , Eli Lilly, dalliance Organizations: Wednesday, HIMS, Novo Nordisk
Helen of Troy — The housewares stock plummeted nearly 28%, hitting a new 52-week low during the session. The company posted an earnings miss for its first quarter of fiscal 2025 before the bell, earning 99 cents per share, excluding items. Lucid — The electric vehicle company's stock added nearly 1% after rallying about 8% in the previous session. Lucid jumped after the firm said it delivered 2,394 vehicles in the second quarter, marking a 70% year-over-year increase. Tesla — Shares of the electric vehicle company popped more than 4%.
Persons: Blackwell, Helen of Troy —, FactSet, UiPath, Lucid, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Corning, Yun Li, Pia Singh, Sarah Min, Darla Mercado Organizations: Nvidia, UBS, BP — U.S, Novo Nordisk, Novo Nordisk's Ozempic, Sony, Paramount, National Amusements, Skydance Media, Apollo, CNBC Locations: Novo
Check out the companies making headlines in midday trading: Nvidia — Shares of the artificial intelligence darling fell 1% after a rare negative call on Wall Street . New Street Research downgraded Nvidia to hold from buy, citing limited upside given the big run already this year. Crypto stocks — Stocks tied to the cryptocurrency plummeted after the trustee for the now defunct Mt. SoftBank Group , Arm Holdings — U.S. shares of SoftBank rose 5.5% after Japanese shares hit their first record high in 24 years on Thursday. Teck Resources — The stock rose more than 2% after Bloomberg reported Thursday that Canada had approved Glencore's $6.9 billion acquisition of Teck's metallurgical coal business.
Persons: Macy's, Stocks, Energy, CleanSpark, Masayoshi, SoftBank, Nio, Zeekr, Li, Emmanuel Papadakis, Teck, Alex Harring, Jesse Pound Organizations: Nvidia, New, Research, Street Journal, Arkhouse Management, Brigade Capital Management, Marathon, SoftBank, Arm Holdings —, Reuters, Francisco Partners, KKR, , European Union, Li Auto, Novo Nordisk, Novo Nordisk's Ozempic, Deutsche Bank, Harvard Medical, Bloomberg, Getty Locations: SoftBank, Europe, Novo, Teck
Crypto stocks — Stocks tied to bitcoin price slid after the cryptocurrency dropped 5% to its lowest level since February , with the now defunct Mt. Macy's — Shares of the retailer jumped more than 6% following a Wall Street Journal report that an investor group has hiked its takeout offer. Arkhouse Management and Brigade Capital Management are now offering about $24.80 per share for Macy's, up from $24 previously, the report said. Tesla — The electric vehicle manufacturer popped 2%, marking a continuing comeback after its second-quarter vehicle deliveries number beat analyst estimates earlier this week. Shell — Shares popped 1%.
Persons: Stocks, Energy, CleanSpark, Instructure, Tesla, CNBC's Hakyung Kim, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: Marathon, Francisco Partners, KKR, Reuters, Macy's, Journal, Arkhouse Management, Brigade Capital Management, Novo Nordisk —, Harvard, Novo Nordisk's Ozempic, Deutsche Bank, Shell Locations: Novo, Singapore, Rotterdam
Check out the companies making headlines in midday trading: SolarEdge Technologies — Shares of the company tumbled more than 20% following the announcement that it will offer $300 million worth of convertible notes due 2029. — The stock plunged more than 7% after the company updated its earnings guidance for the full year on Monday after the bell. The wholesale pool supplies distributor expects full-year earnings between $11.04 and $11.44 per share. Carnival — Shares added nearly 8% after the cruise company posted a second-quarter earnings and revenue beat. Penn Entertainment — The casino operator and online gambling platform's stock fell 5% after Raymond James downgraded it to market perform from outperform.
Persons: Leslie's, LSEG, Raymond James, Enovix, Rivian, , Alex Harring, Lisa Kailai Han, Jesse Pound Organizations: U.S . Securities, Exchange, Pool Corp, Carnival, Penn Entertainment, Airbus, Nvidia —, Novo Nordisk, Guggenheim, Spirit AeroSystems, Boeing, Bloomberg Locations: Singapore, France, China
Nvidia — Semiconductor companies rose broadly as a group, with the VanEck Semiconductor ETF gaining 1.5% in the premarket. Intel shares rose 1.7%. Kroger — Shares rose 6% after the supermarket chain reported fourth-quarter better-than-expected earnings. Analysts expected a profit of 50 cents per share on revenue of $1.67 billion, according to LSEG. Victoria's Secret expects $6 billion full-year revenue, less than the $6.2 billion expected from analysts polled by FactSet.
Persons: Eli Lilly, Mizuho, LSEG, Tesla, NYCB, — CNBC's Michelle Fox, Hakyung Kim, Jesse Pound, Pia Singh Organizations: Nordisk —, Nvidia — Semiconductor, VanEck Semiconductor, Nvidia, Micron Technology, Stifel, Broadcom, Intel, Kroger, Eagle Outfitters, Citi, York Community Bancorp, FactSet, York Community Locations: Danish, American
Victoria's Secret said it anticipates a larger-than-expected decline in revenues for the first quarter and full year. Novo Nordisk — Shares rallied nearly 8.9% to record high level after the company reported positive Phase I trial results for its new experimental weight loss drug amycretin. The company reported adjusted earnings of 61 cents per share on $1.68 billion in revenue for its fiscal fourth quarter. Analysts had estimated earnings of 50 cents per share on $1.67 billion in revenue, according to LSEG. Burlington Stores — The stock rose 7.5% after Burlington posted a fourth-quarter beat on adjusted earnings per share and revenue.
Persons: Victoria's, amycretin, TD Cowen, Shake Shack's, Kroger, LSEG, Iberdrola, Avangrid's, Mizuho, , Samantha Subin Organizations: Novo Nordisk —, American Eagle Outfitters, Burlington Stores, Burlington, New York Community Bancorp, Liberty Strategic, VanEck Semiconductor, Nvidia, Micron Technology, Stifel, Intel, Bloomberg Locations: Spanish
McDonald's posted adjusted earnings of $2.95 per share on $6.41 billion in revenue. Analysts had expected earnings of $2.82 per share and $6.45 billion in revenue, according to LSEG, formerly known as Refinitiv. Analysts polled by FactSet forecast earnings of $2.30 per share on $8.9 billion in revenue for the fourth quarter. The company posted adjusted earnings of 69 cents per share on revenue of $13.32 billion. Caterpillar reported adjusted earnings of $5.23 per share on revenue of $17.07 billion.
Persons: Goldman Sachs, McDonald's, Eli Lilly, Jim Umpleby, Estée Lauder —, Dali Rajic, , Macheel, Jesse Pound, Hakyung Kim, Alex Harring, Michelle Fox, Sarah Min, Darla Mercado Organizations: Nvidia, Novo Nordisk —, Novo Holdings, Novo Nordisk, Management, U.S . Food, Boeing —, Boeing, Tyson, Caterpillar, Air Products, Chemicals, Reuters Locations: Novo, U.S
Jim said, "I don't know if [CEO] Carol Tome can keep the job." The fact is, he added, e-commerce is very strong and "she's not participating in it." Walmart — Founder Sam Walton liked the idea that people shouldn't have to own fractional shares, Jim said, praising the retailer's 3-for-1 stock split . "Very smart move by Walmart" to entice the individual investor with a smaller share price, Jim added. General Motors — Shares on Wednesday added to their 7.8% gain in the prior session on a strong quarter and 2024 guidance.
Persons: Jim, Carol Tome, Sam Walton, Mary Barra, Dave Calhoun didn't, Calhoun, Ozempic, Eli Lilly, Lilly, Tesla, Elon Organizations: Parcel Service, Walmart, General Motors, GM, CNBC, Club, Ford Motor, Boeing, Novo Nordisk — Locations: Delaware
CNBC's Jim Cramer on Monday said the increasing popularity of GLP-1 drugs — medications used to treat diabetes and obesity — has created some new investing opportunities. "Because if you really believe tons of people will take these weight loss medications, to the point where it'll have a transformational impact on the economy, well that's going to create lots of winners, too." Cramer said GLP-1 drugs can cause patients to lose muscle as well as fat, so doctors are encouraging them to consume more protein. Cramer said he also sees potential in the apparel space, with consumers likely to need new clothes to accommodate their weight loss. "When the market was ugly, everyone was worried about how much money the food companies would lose from these GLP-1 weight loss drugs," he said.
Persons: CNBC's Jim Cramer, Monday, , Cramer, Wall, Eli Lilly, Tyson, GLP, Chip Bergh, we're Organizations: Novo Nordisk —, Tyson Foods, Jacobs
Earlier: Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovU.S. drug regulators have approved expanding the use of Eli Lilly ’s diabetes drug Mounjaro to include the treatment of obesity. The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk —that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Eli Lilly ’, Ozempic Organizations: Novo Nordisk Locations: Elizabeth Smelov U.S, Novo
Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic's kidney disease treatment trial after a committee said an analysis showed signs of success. DaVita , Fresenius Medical Care , Baxter International — Shares of dialysis services providers DaVita and Fresenius Medical Care sank 18.4% and 19.6%, respectively, on Novo Nordisk's news. Exxon Mobil , Pioneer Natural Resources — Exxon Mobil shares fell more than 4% after the largest U.S. oil and gas producer agreed to buy shale rival Pioneer Natural Resources for $59.5 billion in an all-stock deal, or $253 per share. Amgen — The biopharma stock added 3.5% following an upgrade from Leerink to outperform. On Wednesday, B. Riley upgraded shares to buy from neutral, saying Coherent's silicon carbide business could be worth more than the Street's current estimate.
Persons: Eli Lilly, Bruce Broussard, Jim Rechtin, Amgen, David Risinger, Goldman Sachs, Jeffrey Brown, Tim Wentworth, Riley, Raymond James, — CNBC's Michael Bloom, Hakyung Kim, Yun Li, Lisa Han Organizations: Novo Nordisk, Novo Nordisk —, Baxter, Fresenius, Novo Nordisk's, Baxter International, Exxon Mobil, Natural Resources, Exxon, Exxon's, Mobil, Healthcare, Goldman, Walgreens, Alliance Locations: Danish, Novo
Plug Power — The battery stock added nearly 6% after the company projected a sharp rise in revenue by 2027 to roughly $6 billion, according to a regulatory filing. DaVita , Novo Nordisk — Shares of the dialysis services provider sank 15% on the news of Ozempic's effectiveness in Novo Nordisk's kidney disease treatment study. Exxon Mobil, Pioneer Natural Resources – Shares of Exxon Mobil were lower by more than 1% premarket after the company agreed to buy Pioneer for nearly $60 billion, or $253 per share, in an all-stock merger. Meanwhile, Pioneer shares rose 2.5%. CSX — Shares added nearly 2% after an upgrade to overweight from JPMorgan.
Persons: Michael Feniger, Raymond James, Humana, Bruce Broussard, Sherwin, Williams, Heidi G, Petz, David Risinger, Macheel, Pia Singh, Michelle Fox Organizations: Mobil, Bank of America, Novo Nordisk —, Novo Nordisk, Exxon Mobil, Natural, Exxon, CSX, JPMorgan, Leerink Partners Locations: Los Angeles , California, Novo
Roku also lifted its third-quarter revenue guidance, saying it now expects revenue to range between $835 million and $875 million, versus prior guidance of $815 million. Along with the workforce reductions, Roku said it plans to consolidate office space and review its content slate to trim expenses. Zscaler posted adjusted earnings of 64 cents per share while analysts polled by LSEG, formerly known as Refinitiv, expected 49 cents. Additionally, the cybersecurity company said earnings and revenue should come in ahead of what analysts anticipate in the current quarter. GitLab — Shares of the technology platform jumped 6.5% in premarket trading following a strong second-quarter report postmarket Tuesday.
Persons: Roku, Zscaler, Needham, GitLab, LSEG, Asana, AeroVironment, Sam Subin, Michelle Fox Theobald, Jesse Pound Organizations: LSEG, Revenue, Dominion Energy, Dominion, UBS, Southwest Airlines —, Southwest, Novo Nordisk — Locations: Hastings, Hudson , New York, Enbridge, Dallas, Danish, Europe
The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. Palantir Technologies — Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Beyond Meat reported an adjusted loss of 83 cents per share on $102.1 million in revenue, while Refinitiv forecasted 86 cents and $108.4 million. Paramount Global — The media conglomerate's shares climbed more than 2% in premarket trading after the company reported a quarterly earnings and revenue beat.
Persons: Goldman Sachs, NASH, Banks, Moody's, Eli Lilly, EchoStar, Charlie Ergen, Refinitiv, Lucid, Palantir, Hims, Simon & Schuster, Yun Li, Samantha Subin, Sarah Min, Pia Singh, Jesse Pound Organizations: Sagimet, Goldman, T Bank, Citizens Financial, Bank of New York Mellon, Truist, JPMorgan Chase, Telsey, Refinitiv, Novo Nordisk —, Dish, United Parcel Service, behemoth, UPS, Palantir, Paramount Global, Paramount, KKR Locations: New York, Banks —
The health care company reported earnings per share of $1.31. Organon posted $1.61 billion in revenue, beating analysts' expectations of $1.57 billion. Beyond Meat — The plant-based meat company fell 16% during midday trading after missing on second-quarter revenue, citing weak U.S. demand. The fragrance and cosmetics company reported revenue of $2.93 billion, falling shorter than analysts' estimates of $3.07 billion, according to StreetAccount. See Corp. — Shares of the packaging company lost 7% after See missed revenue expectations for the second quarter.
Persons: Moody's, Goldman Sachs, JPMorgan Chase, Organon, StreetAccount, Chegg, Charlie Ergen, EchoStar, Eli Lilly —, Eli Lilly, Palantir, , Samantha Subin, Jesse Pound, Alex Harring, Hakyung Kim Organizations: PNC Financial, Citizens, T Bank —, T Bank, Webster, PNC, JPMorgan, Nordisk —, Technologies, Refinitiv . Fox Corp, Corp,
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.
Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S
Shutterstock — Shares of the stock image, video and music provider jumped 10% after Shutterstock announced a six-year, expanded partnership with OpenAI, the maker of ChatGPT. Newell Brands — Shares of the consumer goods company jumped more than 10% after Canaccord initiated its coverage with a buy rating. Salesforce — Shares gained more than 2% after the software company announced it would hike prices across its cloud-based offerings starting in August. Scotts Miracle-Gro — Scotts Miracle-Gro shares gained 7% after Truist upgraded the stock to buy from hold. U.S. Bancorp — Shares gained more than 3% after Bank of America upgraded them to buy from neutral, saying earnings and strong execution should foster outperformance.
Persons: Shutterstock, ChatGPT, Canaccord, Zillow, Piper Sandler, Wells Fargo, Goldman Sachs, Goldman, Xpeng, JPMorgan Chase, Jefferies, Wegovy, Gro —, Generac, , Alex Harring, Michelle Fox, Sarah Min, Yun Li Organizations: OpenAI, Newell, Bank of America, Amazon, Amazon Web Services, Prime, JetBlue Airways —, American Airlines, JPMorgan, Novo Nordisk — Novo Nordisk, Reuters, Scotts Miracle, Gro, Miracle, Truist, Argus Research, Bancorp — Locations: underperform, Xpeng —, Xpeng, U.S
Credit Suisse analyst Trung Huynh has combed through social media and is impressed by the awareness — and demand — for GLP-1 medications such as Eli Lilly 's Mounjaro. Among those observations are reports of other potential benefits that patients taking Mounjaro, or tirzepatide, are seeing. Others taking the drug reported benefits such as a reduction in addiction behaviors such as smoking, drinking, gambling and shopping, among other things. However, this may be a function of patients who are trying to use Mounjaro off-label for obesity, he said. Credit Suisse has an outperform rating on Lilly shares, with a $490 price target, which implies more than 9% upside from where Lilly shares closed Wednesday.
Persons: Trung Huynh, Eli Lilly, Huynh, Mounjaro, agonism, Lilly hasn't, semaglutide —, Lilly, , Michael Bloom Organizations: Credit Suisse, Food and Drug Administration, Novo Nordisk
Total: 25